致幻剂作为变革性治疗手段
本文综述了近十年致幻剂作为难治性神经精神疾病潜在变革性治疗的研究进展。文章涵盖对其治疗机制生物学与药理学的最新理解、药物发现的新努力,以及作为新兴治疗广泛应用时需警惕的潜在陷阱。
要点
- 致幻剂被宣称可治疗抑郁、丛集性头痛、偏头痛、焦虑和强迫症等多种神经精神障碍。
- 基础科学历史上多将致幻剂作为探针研究内源性神经递质系统,主要是5-HT2A受体。
- 需理解其治疗机制的生物学与药理学,并揭示广泛用作治疗时的潜在陷阱。
核心结论
- 致幻剂已成为多种难治性神经精神疾病的潜在变革性治疗,但需理解其治疗机制并警惕广泛应用的潜在陷阱。
研究设计与样本
- 本文为综述,覆盖理解致幻剂生物学机制的最新进展、药物发现的最新努力及作为新兴治疗的潜在陷阱。
主要发现
- 过去十年致幻剂作为多种难治性神经精神疾病的潜在变革性治疗出现。
- 基础科学历史上多将致幻剂作为探针研究内源性神经递质系统,主要是5-HT2A受体。
- 临床试验激增,致幻剂被宣称可治疗抑郁、丛集性头痛、偏头痛、焦虑和强迫症等。
临床怎么用
- 临床应理解致幻剂治疗机制的生物学与药理学,并警惕其广泛用作治疗的潜在陷阱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past decade, psychedelic compounds have emerged as potentially transformative therapeutics for a variety of intractable neuropsychiatric conditions. However, historically most of the basic science has utilized these compounds as probes to interrogate various endogenous neurotransmitter systems-mainly the serotonin 5-HT2A receptor. With the renewed interest in utilizing these compounds as therapeutics and the explosion in clinical trials, psychedelics have been purported to treat many neuropsychiatric disorders, including depression, cluster headaches, migraines, anxiety, and obsessive-compulsive disorder. It is therefore imperative to understand the biology and pharmacology behind their therapeutic mechanisms as well as expose any potential pitfalls in their widespread use as treatments. This review covers the latest advances in understanding the biological mechanisms, the newest efforts in drug discovery, and potential pitfalls when it comes to utilizing this class of compounds as emerging therapeutics.
引用
- Roth BL, Gumpper RH. Psychedelics as Transformative Therapeutics. Am J Psychiatry. 2023. PMID: 37122272. doi:10.1176/appi.ajp.20230172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。